Loading
Life sciences · Journal article
Cell & Bioscience · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Adipose tissue plasticity, sustained by the recruitment and differentiation of adipocyte precursor cells (APCs), is a key determinant of metabolic health. Failure of this adaptive program, rather than fat mass per se, represents an early contributing factor in the progression toward insulin resistance (IR) and type 2 diabetes (T2D). Increasing evidence identifies impaired APC function and premature cellular senescence as central mechanistic drivers of adipose tissue dysfunction. In this context, the interplay between DNA methylation and cellular senescence emerges as a central axis linking impaired adipogenesis to adipose tissue dysfunction. Emerging evidence highlights epigenetic dysregulation, particularly aberrant DNA methylation, as a pivotal mechanism controlling adipogenesis, senescence, and metabolic flexibility. DNA methylation dynamically modulates transcriptional programs governing adipocyte commitment and maturation through the interplay of DNA methyltransferases (DNMTs) and ten-eleven translocation (TET) enzymes. In obesity and T2D, disruption of this DNMT/TET balance promotes maladaptive remodeling, persistent inflammatory signaling, and premature cellular senescence, with locus-specific methylation changes affecting key adipogenic regulators that limit APC commitment and differentiation, as documented in human adipose tissue across obesity and diabetes. Senescent APCs acquire a pro-inflammatory secretory phenotype, known as the senescence-associated secretory phenotype (SASP), that spreads dysfunction to neighboring cells and amplifies systemic IR. Understanding this epigenetic–senescence axis may provide a framework for therapeutic intervention. Epigenetic modulators such as DNMT inhibitors (DNMTis) and TET activators, alongside senolytic and senomorphic agents, have shown promising preclinical results in restoring adipose function. Complementary lifestyle interventions, including caloric restriction (CR) and exercise, further remodel the adipose epigenome toward a metabolically favorable state. Targeting both epigenetic mechanisms and cellular senescence may represent a promising strategy to improve adipose function and metabolic outcomes and restore metabolic flexibility.